These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20661082)

  • 1. Pem and the cost of multicycle maintenance.
    Learn PA; Bach PB
    J Thorac Oncol; 2010 Aug; 5(8):1111-2. PubMed ID: 20661082
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
    J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. Rev Port Pneumol 2008; 14(6):803-827.
    Bartminski W
    Rev Port Pneumol; 2009; 15(3):555-9; author reply 560-6. PubMed ID: 19526635
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC).
    Mueller E
    Lung Cancer; 2010 Aug; 69 Suppl 1():S1-3. PubMed ID: 20727456
    [No Abstract]   [Full Text] [Related]  

  • 5. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
    Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
    Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
    Vergnenegre A; Corre R; Berard H; Paillotin D; Dujon C; Robinet G; Crequit J; Bota S; Thomas P; Chouaid C;
    J Thorac Oncol; 2011 Jan; 6(1):161-8. PubMed ID: 21150465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system.
    Matter-Walstra K; Joerger M; Kühnel U; Szucs T; Pestalozzi B; Schwenkglenks M
    Value Health; 2012 Jan; 15(1):65-71. PubMed ID: 22264973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed for the treatment of non-small cell lung cancer.
    Genova C; Rijavec E; Truini A; Coco S; Sini C; Barletta G; Dal Bello MG; Alama A; Savarino G; Pronzato P; Boccardo F; Grossi F
    Expert Opin Pharmacother; 2013 Aug; 14(11):1545-58. PubMed ID: 23683110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact analysis of pemetrexed introduction: case study from a teaching hospital perspective, Thailand.
    Chanjaruporn F; Roughead EE; Sooksriwong CO; Kaojarern S
    J Med Assoc Thai; 2011 Sep; 94(9):1026-34. PubMed ID: 21970190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?
    Guirgis HM
    J Oncol Pract; 2012 Jul; 8(4):224-30. PubMed ID: 23180986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer.
    Pérez-Moreno MA; Galván-Banqueri M; Flores-Moreno S; Villalba-Moreno A; Cotrina-Luque J; Bautista-Paloma FJ
    Int J Clin Pharm; 2014 Jun; 36(3):476-87. PubMed ID: 24590919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.
    Nadler E; Forsyth M; Satram-Hoang S; Reyes C
    J Thorac Oncol; 2012 Jan; 7(1):212-8. PubMed ID: 22124474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
    Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
    Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
    Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.
    Doral Stefani S; Giorgio Saggia M; Vicino dos Santos EA
    J Med Econ; 2008; 11(3):383-96. PubMed ID: 19450094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Wielage R; Muehlenbein C; Liepa AM; Babineaux S; Lawson A; Schwartzberg L
    J Thorac Oncol; 2010 Aug; 5(8):1263-72. PubMed ID: 20581708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More than 54 months survival of a patient with lung adenocarcinoma after maintenance therapy with pemetrexed.
    Samelis G; Ekmektzoglou K; Giannakaki S; Tsiakou A
    J BUON; 2010; 15(4):797. PubMed ID: 21229649
    [No Abstract]   [Full Text] [Related]  

  • 19. Pemetrexed: current development and future directions in thoracic cancers.
    Manegold C
    Suppl Tumori; 2002; 1(4):S11-2. PubMed ID: 12415805
    [No Abstract]   [Full Text] [Related]  

  • 20. Comment and reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective.
    Arellano J; Leteneux C
    J Med Econ; 2008; 11(2):363-66; author reply 366-70. PubMed ID: 19450092
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.